Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon 25000 for pancreatic exocrine insufficiency after total gastrectomy
2023-507837-18-00Phase 4Authorised
- Sponsor
- BGP Products Operations
- Start
- Jan 2025
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Blood Coagulation Factors → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 4, open-label, single-arm trial of pancreatin in exocrine pancreatic insufficiency (EPI), sponsored by BGP Products Operations. Primary endpoint: Proportion of patients without deterioration of nutritional status on stable Creon dose. Planned start Jan 2025; status: authorised.
02
Drugs
pancreatin
03
Conditions
exocrine pancreatic insufficiency (EPI)
Beyond the preview
Go deeper on 2023-507837-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507837-18-00.